


INDICATED IN ADULTS



- Urinary tract infections
- Lower respiratory tract infections
- Bloodstream infections

Where susceptible Gram-negative bacilli are suspected or confirmed.

DOSAGES


Usual dose
2g BD or
4g/24h continuous infusion*

High dose**
2g TDS or
6g/24h continuous infusion*


Dose adjustments are necessary in case of moderate and severe renal failure

*a loading dose of 2g should be administered before starting the infusion

**notably in critically ill patients



ᶜtherefore active against most multi-drug resistant Gram negative bacteria (ESBL/AmpC)
ᵇlow ecological pressure¹⁰, less diarrhoea³ & low prevalence of *C. difficile* infections¹¹



EUMEDICA
Pharmaceuticals

www.eumedica.com

Scientific information and SPC available on request • enquiries@eumedica.com
Adverse events should be reported: reporting information can be found at <www.yellowcards.gov.uk> and should also be reported to Eumedica SA

¹Balokrishnan I et al. J Antimicrob Chemother. 2011;66(11):2628-31

²Summary of product characteristics - Negaban 1 g powder for solution for injection/infusion - Date of revision of the text: 26/01/20

³Habayeb H et al. Eur J Clin Microbiol Infect Dis. 2015;34(8):1693-9 ⁴Latere PF et al. J Antimicrob Chemother. 2015;79(3):691-8

⁵De Jongh H et al. J Antimicrob Chemother. 2008;61(3):362-8 ⁶Livermore D et al. J Antimicrob Chemother. 2006;57(5):1012-4

⁷Woodford N et al. J Antimicrob Chemother. 2014;69(2):564-7 ⁸Livermore D et al. J Antimicrob Chemother. 2009;63(2):243-5

⁹Alexandre K et al. Clin Pharmacokinet. 2018;57(3):287-96 ¹⁰Mittlermayer HW, Drugs. 1985;29(Suppl 5):43-8

¹¹Boon RJ and Beale AS, Antimicrob Agents Chemother. 1985;27(6):980-1 ¹²Habayeb H et al. Int J Antimicrob Agents. 2018;52(3):43